Investors

Company Information

The Company was incorporated and registered in England and Wales on 13 February 2013 as a private limited company and re-registered on 25 November 2014 as a public limited company. The Company’s wholly owned US operating subsidiary, Hemogenyx Pharmaceuticals LLC, is incorporated in the state of Delaware.

Registered Office

6th Floor60 Gracechurch Street, London, EC3V 0HR, United Kingdom
Company registered in England & Wales, No. 08401609


Articles of Association

The Company’s current Articles of Association


Employee Incentive Plan

The 2021 Employee Incentive Plan approved by the Board of Directors on 27 July 2021 and by the shareholders at the annual general meeting of 30 June 2022


Prospectuses

The Prospectus for the investment in Hemogenyx Pharmaceuticals by Mint Capital published on 29 January 2021

A Supplementary Prospectus was published on 12 My 2021 following publication of the Company’s annual report for 2020

The Prospectus for Hemogenyx Pharmaceuticals upon admission to the LSE on 5th October 2017


Documents re. the acquisition of Hemogenyx Pharmaceuticals plc by Silver Falcon plc

Corporate Governance

The Company observes the requirements of the UK Corporate Governance Code. The Company is in compliance with the UK Corporate Governance Code, save as set out below:

Each of the Directors has been briefed on their obligations and has signed up to a protocol relating to the management and dissemination of confidential information so as to ensure that the Company and its Directors comply with the provisions of the Market Abuse Regulation and the requirement to ensure that any inside information and other confidential information remains properly collated, recorded and held confidential.

The Company has established audit, remuneration and nomination committees.

Audit Committee

The Audit Committee has responsibility for, among other things, the monitoring of the integrity of the financial statements of the Company and its Enlarged Group and the involvement of the Group’s auditors in that process. It focuses in particular on compliance with accounting policies and ensuring that an effective system of external audit and financial control is maintained, including considering the scope of the annual audit and the extent of the non-audit work undertaken by external auditors and advising on the appointment of external auditors. The ultimate responsibility for reviewing and approving the annual report and accounts and the half-yearly reports remains with the Board. The Audit Committee will meet at least three times a year at the appropriate times in the financial reporting and audit cycle.

The members of the Audit Committee are Peter Redmond, who acts as chairman of the committee, and Professor Sir Marc Feldmann, and the Financial Controller attends its meetings.

Remuneration Committee

The remuneration committee reviews the performance of the executive directors and makes recommendations to the Board on matters relating to their remuneration and terms of employment. The committee also makes recommendations to the Board on proposals for the granting of share awards and other equity incentives pursuant to any share award scheme or equity incentive scheme in operation from time to time. The Remuneration Committee meets at least twice a year.

The members of the Remuneration Committee are Peter Redmond, who acts as chairman of the committee, and Alexis Sandler.

Nomination Committee

The Nomination Committee is responsible for considering and making recommendations to the Board in respect of appointments to the Board, the Board committees and the chairmanship of the Board committees. It is also responsible for keeping the structure, size and composition of the Board under regular review, and for making recommendations to the Board with regard to any changes necessary, taking into account the skills and expertise that will be needed on the Board in the future. The Nomination Committee meets at least once a year.

The members of the Nomination Committee are Peter Redmond, Alexis Sandler, Peter and Professor Sir Marc Feldmann.

Corporate Advisers

The Company observes the requirements of the UK Corporate Governance Code. The Company is in compliance with the UK Corporate Governance Code, save as set out below:

Each of the Directors has been briefed on their obligations and has signed up to a protocol relating to the management and dissemination of confidential information so as to ensure that the Company and its Directors comply with the provisions of the Market Abuse Regulation and the requirement to ensure that any inside information and other confidential information remains properly collated, recorded and held confidential.

Registered Office

6th Floor
60 Gracechurch Street
London
EC3V 0HR
United Kingdom


Registrar

Computershare Investor Services PLC
The Pavilions
Bridgwater Road
Bristol
BS13 8AE

Joint Broker

SP Angel Corporate Finance LLP
35 Maddox St
Mayfair
London
W1S 2PP


Legal Advisers
To The Company
As To English Law

Cooley (UK) LLP
Dashwood
69 Old Broad Street
London EC2M 1QS

Joint Broker

Peterhouse Capital Limited
80 Cheapside
London
EC2V 6EE


Legal Advisers
To The Company
As To US Law

Rubin & Rudman LLP
50 Rowes Wharf
Boston
Massachusetts 0211

Cooley LLP
500 Boylston Street
Boston, MA 02116-3736

Auditors And Reporting
Accountants

PKF Littlejohn LLP
Westferry Circus
Canary Wharf
London
E14 4HD

Shareholder Information

Shares Issued

The number of shares in issue was 1,141,999,321.

AS AT 2 FEBRUARY 2023

Significant Shareholders

None known at present time except for Director shareholdings

AS AT 2 FEBRUARY 2023

Director Shareholdings

AS AT 2 FEBRUARY 2023

DIRECTORNUMBERORDINARY SHARES %
Alexis Sandler75,090,6856.58
Dr Vladislav Sandler41,544,6773.64
Peter Redmond5,596,2700.49

Shares Not In Public Hands

Insofar as it is aware, 16.74% of the Company’s securities were not in public hands.

AS AT 2 FEBRUARY 2023

UK City Code On Takeovers And Mergers

The Company is subject to the provisions of the City Code on Takeovers and Mergers.

Shareholder Circulars

Annual and Half Year Reports, together with historical general meeting notices, blank proxy voting forms, and other shareholder circulars

Most rated shareholder circular:

8 JUNE 2021

Notice of Annual General Meeting to be held on 30 June 2022 and 2021 Equity Incentive Plan with Non-Employee Sub-Plan proposed for approval at the AGM

Other Exchanges And Trading Platforms

Hemogenyx Pharmaceuticals plc has not applied or agreed to have any of it securities admitted or traded on any other exchanges or trading platforms.

Share Data

Read about the Company’s share price, trading data and other technical information on our shares

Profile

Hemogenyx Pharmaceuticals (HEMO)

SECTOR Pharmaceuticals & Biotech

Minimum 15 minutes delayed

Company Listing Data

EPICHEMO
SECTORPharmaceuticals & Biotech
SEDOLBYX3WZ2
ISINGB00BYX3WZ24
Market SectorMain Market
Market SegmentSSQ3
Country of registerUK
CurrencyBritish Pence
Date listed22 December 2014

Annual & half-year reports

13 Mar 2024
2023 Half Year Report

2 Jun 2023
Proxy Form (2023 AGM)

2 Jun 2023
AGM Notice (2023 AGM)

31 Dec 2022
2022 Annual Report

29 Sep 2022
2022 Half Year Report

7 Jun 2022
Proxy Form (2022 AGM)

Broker Coverage

SP Angel

The most recent coverage is at the top; scroll down the page for prior coverage.

Videos & Presentations

SP Angel Research – Terms and Conditions

Access to SP Angel’s research via this web site is subject to the following terms and conditions. SP Angel (‘SPA’) does not deal with individual or private investors (save in connection with corporate finance business). SPA’s research is thus not prepared for private investors and does not take into account any particular investor’s or class of investors’ investment objectives. You are therefore not being granted access to SPA research in your capacity as an investor or SPA client or potential investor or client. You understand that SPA is not offering you any financial service. Members of SPA’s Research department are not permitted to interact with private investors and you should not attempt to contact them.